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ABSTRACT
Imaging, cerebrospinal ﬂuid (CSF) and blood-based
biomarkers have the potential to improve the accuracy by
which speciﬁc causes of dementia can be diagnosed in
vivo, provide insights into the underlying pathophysiology,
and may be used as inclusion criteria and outcome
measures for clinical trials. While a number of imaging
and CSF biomarkers are currently used for each of these
purposes, this is an evolving ﬁeld, with numerous
potential biomarkers in varying stages of research and
development. We review the currently available
biomarkers for the three most common forms of
neurodegenerative dementia, and give an overview of
research techniques that may in due course make their
way into the clinic.
INTRODUCTION
A biomarker is a characteristic that can be object-
ively measured and evaluated as an indicator of
normal biological or pathogenic processes or
pharmacological responses to a therapeutic interven-
tion.1 An ideal biomarker is reproducible, stable
over time, widely available and reﬂects directly the
relevant disease process.1 For the dementias, bio-
markers may be used to distinguish different aspects
of the underlying pathology; detect presymptomatic
pathological changes; predict decline or conversion
between clinical disease states; and/or monitor
disease progression and response to treatment. In
this review we provide an overview of currently
available biomarkers, with a particular focus on the
three commonest neurodegenerative dementias:
Alzheimer’s disease (AD), frontotemporal dementia
(FTD) and dementia with Lewy bodies (DLB).
BIOMARKERS OF DEMENTIA CURRENTLY IN
CLINICAL USE
Biomarkers in dementias can be divided into
imaging modalities, which are already widely used
in clinical and research settings; and cerebrospinal
ﬂuid (CSF) measures whose clinical use varies
widely between countries and centres. Currently,
no blood-based or urine-based biomarkers are
available for routine clinical use.
Imaging
Structural brain imaging
Structural brain imaging (CT or MRI) is recom-
mended in all patients being investigated for demen-
tia, according to UK, European and US guidelines.2
Moving away from excluding ‘surgical’ causes (eg,
mass lesions) of cognitive impairment, structural
imaging (and MRI in particular) can usefully assess
vascular damage, white matter signal changes with a
wide range of causes,3 and spongiform and gliotic
changes as seen in prion disease. The pattern of
regional brain loss (atrophy) reﬂecting neuronal loss
has positive predictive value for different demen-
tias2 and is incorporated into diagnostic criteria for
several dementia syndromes (discussed below).
Atrophy can be assessed using simple visual rating
scales or more complex quantitative manual or auto-
mated techniques. Serial imaging—particularly with
MRI, which provides superior grey/white contrast
without radiation exposure—is widely used as safety
and outcome measures for clinical trials, with rates
of atrophy considered surrogate markers of
neurodegeneration.
Functional imaging
Positron emission tomography (PET) using
18-F-ﬂourodeoxyglucose (FDG) and single photon
emission tomography (SPECT) using tracers such
as 99mTc-hexamethylpropyleneamine (HMPAO),
allows for visualisation and quantiﬁcation of patterns
of brain hypometabolism and hypoperfusion which
show characteristic patterns that differ in different
dementia syndromes.4 Dopamine transporter scan-
ning can be used to determine central dopaminergic
depletion, as seen in DLB, Parkinson’s disease demen-
tia, as well as a range of other movement disorders
associated with dementia.5 The development of PET
tracers that bind to and label-speciﬁc brain proteins,
including ﬁbrillar amyloid or Tau allows for aspects of
the molecular pathology underlying certain dementias
—and AD in particular—to be imaged in vivo.6
Functional MRI (fMRI) measures alterations in
regional cerebral blood ﬂow using a linked blood–
oxygen-level-dependent (BOLD) signal change in
the magnetic properties of cerebral venous blood.
fMRI techniques can measure intrinsic ﬂuctuations
in BOLD signal in the waking brain at rest (‘resting
state’ or rsfMRI) or BOLD changes in response to
a particular stimulus or task in the scanner (‘activa-
tion’ fMRI). At present fMRI techniques require
considerable expertise and a dedicated infrastruc-
ture to implement and analyse, which limits their
widespread application as biomarkers.
Fluid biomarkers
Cerebrospinal ﬂuid
In the context of dementia, CSF examination has
traditionally been used to exclude infection, malig-
nancy and neuroinﬂammation, as reﬂected by
guidelines recommending CSF examination in
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individuals with cognitive impairment under the age of 55, indi-
viduals with rapid disease course, ‘unusual’ dementia syndromes
or those who are immunosuppressed.7 In degenerative forms of
dementia, the cell count is not usually raised, and there is no
evidence for CNS-speciﬁc immune responses. Where abnormal-
ities are present, these should prompt consideration of unusual
forms of dementia, including infectious and inﬂammatory con-
ditions.7 In cases of rapidly progressive dementia, the presence
of a positive 14-3-3 protein, elevated S100B, elevated total-tau
tau to phospho-tau ratio, and recently the use of real-time
quaking-induced conversion (RT-QUIC) technology8 have posi-
tive predictive value for prion disease. CSF analysis using a
variety of immunochemical techniques allows a range of
neuronal-speciﬁc or neuronal-enriched proteins to be measured
(see below). The use of neuronal-enriched CSF markers
β-amyloid and tau in the routine evaluation of patients with
dementia varies considerably between countries and between
clinicians; these markers have been incorporated into new AD
diagnostic criteria (see below, and table 2), and are increasingly
included as inclusion/outcome measures for clinical trials. There
is considerable variability in the methods used to collect and
analyse CSF, leading to initiatives to harmonise preanalytical
handling and standardise laboratory practices (see table 1).
Developing normal reference ranges and reliable cut points for
clinical use in the absence of postmortem conﬁrmation of the
underlying pathology is a signiﬁcant challenge.9
Blood and urine
While there are obvious advantages of blood-based or urine-
based biomarkers for dementias, to date none have found utility
in clinical practice. Brain derived proteins exist in much smaller
concentrations in peripheral blood or urine than in CSF, due to
the function of the blood–brain barrier and the large total
volume of blood and urine in which they are diluted; further
complications include signiﬁcant binding of many proteins of
interest and rapid clearance from the blood, which may make
many conventional assays insufﬁciently sensitive. This may
change with the development of more sensitive metabolomic and
proteomic approaches being used for biomarker discovery.10
Online supplementary table shows the currently available bio-
markers and those in current development.
BIOMARKERS OF AD
AD is the commonest cause of dementia particularly in older
individuals,11 and is characterised neuropathologically by
amyloid plaques and tau containing neuroﬁbrillary tangles.
Other pathological changes include the presence of activated
microglia around amyloid plaques12 and amyloid angiopathy
and microhaemorrhages in some individuals with AD.13 Most
cases of AD are sporadic, with autosomal dominant mutations
in either the presenilin 1 (PSEN1), presenilin 2 (PSEN2) or
amyloid precursor protein (APP) genes accounting for <1% of
cases. In sporadic AD more than 20 genetic risk factors have
been identiﬁed, implicating cholesterol transport, innate immun-
ity and endosomal vesicle recycling in pathogenesis.14
Progressive impairment of episodic memory is the commonest
clinical presentation of AD; rarer focal presentations include
posterior cortical atrophy, logopenic aphasia (LPA) and a dysex-
ecutive presentation.15 In clinical practice there is often signiﬁ-
cant overlap between these syndromes and a merging of
symptoms as the disease progresses. The original clinical criteria
for AD16 did not acknowledge this phenotypic diversity, and by
requiring that an individual have dementia and multidomain
cognitive impairment, precluded the early symptomatic and pre-
symptomatic stages of AD. Newer criteria place an emphasis on
using biomarkers to provide an earlier and more speciﬁc diagno-
sis17 18 (table 2). For research purposes only, this may extend to
the prodromal phase of the disease, which may begin a decade
or more before cognitive impairment occurs.17 19
Table 1 Optimal practice for CSF collection and processing
Confounding variable Ideal situation
Preanalytical factors
Time of collection 8:00–12 noon to avoid potential for diurnal variation in CSF biomarkers
LP needle Needle gauge or design not known to influence measured biomarker concentration but gauge is related to risk of
post-LP headache. Smallest size practical to use in diagnostic LP is 22G. Atraumatic needles are associated with
reduced post-LP headache but increased failure rate
Use of lumbar catheters/manometers Aβ1-42 may adhere—to be avoided, if possible
Collection vessel Polypropylene tube recommended. Aβ1-42 and other proteins adhere to polystyrene and glass significantly
reducing measured concentrations. Tube brand may also influence measured biomarker concentrations
Fasting Not required
Blood contamination/blood–brain barrier dysfunction Blood contamination of up to 5000 erythrocytes/mL cells does not alter measured biomarker concentration, but
blood–brain barrier dysfunction equivalent to CSF/serum albumin ratio >11 results in reduced measured Aβ1-42
concentration and should be interpreted with care
Optimal volume In addition to CSF collected for routine clinical examination (eg, cell count, oligoclonal bands, cytology, etc)
15 mL can safely be collected without increased risk of post LP headache
Centrifugation Within 30 min of LP at 3000 rpm for 10 min to remove cells and other debris
Aliquot storage volume Samples that are frozen prior to analysis should be stored in aliquots of a standardised volume which fits the tube
size well. Specifically, one should strive for as high volume to surface ratio as possible (well-filled tubes). Volume
to surface ratio and number of tube transfers influence measured Aβ1-42 concentration, probably due to protein
adsorption
Freeze thawing One or less freeze thaw cycles is recommended. Measured Aβ1-42 concentration drops by 20% after 3 freeze
thaw cycles. Aβ1-42 and τ concentrations are stable at temperatures of −80°C
Choice of immunoassay/platform Consistency required; variability in commercially available ELISA-based assays, calibration peptides and platforms
mean interlaboratory and interassay consistency is poor
CSF, cerebrospinal fluid; LB, lumbar puncture.
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Currently used biomarkers and their utility
Structural imaging
In AD, the typical imaging appearance is of global brain atrophy
with early disproportionate symmetrical involvement of medial
temporal lobe structures including the hippocampi.2 The pres-
ence of symmetrical medial temporal atrophy can differentiate
AD from ageing with a sensitivity and speciﬁcity of around 80–
85%20; and in a single centre pathologically proven study, estab-
lished AD from DLB and vascular cognitive impairment with a
sensitivity and speciﬁcity of 91% and 91%, respectively.21 The
presence of medial temporal lobe atrophy per se is unable to dif-
ferentiate AD from FTD in most instances,22 although patterns
of (medial and lateral) temporal lobe atrophy may be very
helpful in identifying speciﬁc FTD subgroups (see below).
Medial temporal lobe atrophy can predict which individuals will
develop clinical AD from a mild cognitive impairment (MCI)
state with a sensitivity and speciﬁcity of 73% and 81%, respect-
ively.20 22 Progressive atrophy of the parietal/occipital lobes is
supportive of AD and in particular in distinguishing AD from
FTD; incorporating visual ratings of posterior atrophy can
improve the distinction of AD from other causes of dementia.2
Rates of whole brain and hippocampal atrophy, calculated from
serial volumetric MRI are sensitive markers of progression of
neurodegeneration and are increasingly used as outcome mea-
sures in trials of potentially disease modifying therapies in AD.22
Functional imaging
The typical AD pattern on FDG-PETor HMPAO-SPECT imaging is
bilateral hypometabolism and hypoperfusion in the temporal and
parietal cortices; the sensitivity and speciﬁcity in diagnosing AD
versus other neurodegenerative diseases has been reported as 79%
and 88%, respectively.23 These changes may predate brain atrophy
or cognitive symptoms, and correlate with disease severity.24
Amyloid PET is a sensitive and speciﬁc means of imaging brain
amyloid in individuals in vivo, and has been shown to correlate
closely with autopsy measures of ﬁbrillar amyloid load,25 and has
considerable potential value in ruling in/out AD pathology as the
cause of cognitive decline in a patient with cognitive impairment.
Several amyloid PET agents are now licensed for clinical use, and
amyloid imaging is now included in criteria for the diagnosis of
AD.15 26 Importantly however as up to a third of elderly non-
demented individuals may have a positive amyloid scan, the signiﬁ-
cance of which is as yet unclear, the clinical utility of amyloid PET
imaging in older individuals is still to be determined and in particular
it is not recommended in cognitively healthy individuals outside of
research studies.17 27 Additionally, the presence of amyloid pathology
does not always equate to a diagnosis of AD, as for instance a pro-
portion of patients with DLB will also have amyloid deposition.28
Current guidelines (eg, by the UK Royal College of Radiologists
and Physicians) advocate the use of amyloid PET in highly selected
individuals with cognitive impairment after evaluation by a
dementia expert where the presence or absence of amyloid path-
ology is expected to increase diagnostic certainty and inﬂuence
management.29 At the time of writing, availability and cost of
amyloid PET imaging has limited its use in clinical practice.
Cerebrospinal ﬂuid
β-Amyloid
CSF levels of Aβ1-42, thought to be one of the key pathological
forms of Aβ in brain tissue, are reduced in AD, with the degree
Table 2 Biomarkers currently used in diagnostic criteria
Criteria Comments
AD
Biomarkers of amyloid pathology: Low CSF Aβ1-42 on CSF examination Positive amyloid PET scan Either evidence of low CSF Aβ1-42 or positive amyloid PET scan
required for diagnosis of amyloid brain deposition15
Biomarkers of neuronal injury: Elevated CSF tau and phospho-tau; Hypometabolism on
FDG-PET; Disproportionate atrophy of medial, basal and lateral temporal lobe, and medial parietal
cortex on structural MRI
Either elevated CSF tau, FDG-PET changes or structural MRI
changes required for a diagnosis of neuronal injury15
McKhann criteria15 require evidence of amyloid pathology and neuronal injury to support a diagnosis of highly probable AD (biomarker evidence only recommended in
individuals who do not meet the core clinical criteria for probable AD dementia).Dubois criteria (IWG2)26 require specific clinical features of AD (typical or atypical) plus
evidence of in vivo AD pathology. Evidence of in vivo AD pathology: low CSF Aβ1-42 together with increased total-tau or phospho-tau or positive amyloid PET or proven
mutation in PSEN1, PSEN2, or APP or other proven genes (including Down’s syndrome trisomy 21).
Frontotemporal dementia
bvFTD
Frontal and/or anterior temporal lobe atrophy on MRI or CT Either structural or PET imaging changes required for a diagnosis
of probable bvFTD100Frontal and/or anterior temporal lobe hypoperfusion or hypometabolism on PET or SPECT
Progressive non-fluent aphasia
Predominant left posterior frontoinsular atrophy on MRI Either structural or PET imaging changes required for an imaging
supported diagnosis58Predominant left posterior frontoinsular hypoperfusion or hypometabolism on SPECT or PET
Semantic dementia
Predominant anterior temporal lobe atrophy Either structural or PET imaging changes required for an imaging
supported diagnosis58Predominant anterior temporal hypoperfusion or hypometabolism on SPECT or PET
Dementia with Lewy bodies
Relative preservation of medial temporal lobe structures on CT/MRI Supportive feature (commonly present but not proven to have
diagnostic specificity)
Generalised low uptake on SPECT/PET perfusion scan with reduced occipital activity Supportive feature (commonly present but not proven to have
diagnostic specificity)
Abnormal (low uptake) MIBG myocardial scintigraphy Supportive feature (commonly present but not proven to have
diagnostic specificity)
Abnormal uptake on PET/SPECT (eg, 123 I-FP CIT- DaTSCAN) Supportive feature (used to differentiate DLB from AD and some
forms of FTD)
AD, Alzheimer’s disease; APP, amyloid precursor protein; bvFDT, behavioural variant frontotemporal dementia; CSF, cerebrospinal fluid; FDG, 18-F-flourodeoxyglucose; MIBG,
metaiodobenzylguanidine ; p-tau, tau phosphorylated at 181; PET, positron emission tomography; SPECT, single photon emission tomography; t-tau, total tau.
1428 Ahmed RM, et al. J Neurol Neurosurg Psychiatry 2014;85:1426–1434. doi:10.1136/jnnp-2014-307662
Cognitive neurology
group.bmj.com on June 8, 2015 - Published by http://jnnp.bmj.com/Downloaded from 
of reduction correlating with brain amyloid plaque load.30
Reduction of CSF Aβ1-42 occurs years before symptom onset,31
and has good positive predictive value for conversion from MCI
to clinical AD32; accordingly CSF Aβ1-42 is now included in
new diagnostic criteria for MCI due to AD.15 In clinical prac-
tice, a normal CSF Aβ1-42 in a demented individual should
prompt re-evaluation of a diagnosis of AD. Conversely however,
a low CSF Aβ1-42, does not always reﬂect brain amyloid depos-
ition, being seen in other conditions including multiple sclerosis,
and more commonly due to CSF being collected, stored or pro-
cessed incorrectly. Other forms of β-amyloid, notably Aβ1-40
can be measured in CSF and may better reﬂect both total brain
Aβ burden than Aβ1-42.33 While some studies have suggested
that addition of CSF Aβ1-40 may improve differential diagnosis
in certain circumstances34 35 this has not yet entered routine
clinical practice.
Tau and Phospho-tau 181
CSF levels of t-tau and tau phosphorylated at 181 (p-tau), are
both increased in AD. Like Aβ1-42, t-tau and p-tau are usually
measured using ELISA-based assays. There are also multiplexed
assays for the three analytes. T-tau is increased after stroke, in
inﬂammatory conditions and in other neurodegenerative dis-
eases—most notably in Creutzfeldt-Jakob disease where levels
are often orders of magnitude higher than in AD; p-tau eleva-
tion is thought to have high speciﬁcity for AD.36 Stability and
reproducibility of t-tau and p-tau levels is good, and levels
remain stable over periods of up to 6 months,37 suggesting that
these biomarkers may be capable of detecting small biochemical
changes induced by treatment. There are at present no data to
support the use of tau/p-tau assays in peripheral blood, due to
tau concentrations being below the lower limit of detection for
most assays in the blood.
Combining CSF biomarkers
In 2006 a longitudinal study of 137 individuals followed for 4–
6 years demonstrated that the combination of low CSF Aβ1-42,
and elevated t-tau and p-tau could distinguish individuals with
MCI/incipient AD from those without with 95% sensitivity and
87% speciﬁcity.38 These ﬁndings have since been replicated in
several other studies.39 40 On a research basis, the combination
of low Aβ42, elevated tau and p-tau has also been used to
predict future cognitive decline in healthy older individuals.41
In clinical practice, the combination of low CSF Aβ1-42 and ele-
vated tau (or p-tau) to Aβ1-42 ratio is often used to support the
diagnosis of AD, with one recent study suggesting that tau:Aβ42
ratio is the most robust single biomarker combination.42
In practice, combining several of these different biomarkers,
each of which provides different insights into the underlying
disease process, may increase diagnostic certainty (see Case
Study ﬁgure 1).
Emerging and future biomarkers
Advanced MRI
Current hypotheses predict that amyloid deposition, tau
mediated neuronal dysfunction, neuroinﬂammation and synaptic
loss precede the development of structural brain changes, that is,
atrophy by several years, which in turn predates cognitive impair-
ment. There is therefore considerable interest in determining
imaging biomarkers to detect and quantify AD-related network
disruption after the emergence of molecular pathology but
before irreversible neuronal loss. Techniques including diffusion
tensor imaging (DTI) and rsfMRI probing white matter tracts
and functional integrity of neuronal networks, respectively, show
promising results in group studies, but are only just being applied
at the individual level. Using rsfMRI, presymptomatic individuals
at increased risk of developing AD have shown altered resting
connectivity in a distributed temporoparietofrontal network
(the so-called default mode network) and altered task-related
Figure 1 Case showing clinical use of biomarkers. A 56 year old
patient presented with a 5–10-year history of ‘scattiness’. Three years
ago she developed difﬁculties reading an analogue clock, her spelling
had declined and she had difﬁculty reading, losing her place from line
to line. She received a clinical diagnosis of posterior cortical atrophy.
Subsequently episodic memory became impaired. At the time of
scanning, the Mini-Mental State Examination score was 19/30. A T1
volumetric MRI of the brain demonstrated a posterior pattern of cortical
atrophy (A) with preserved hippocampal volumes compared with a
healthy control patient (B); A 18F-ﬂorbetpair amyloid positron emission
tomography (PET) scans shows widespread cortical amyloid deposition
(C) compared with a healthy control (D) ﬂudeoxyglucose (18F) PET scan
demonstrates a posterior dominant pattern of hypometabolism (E)
SUVR 1.0–1.4, compared with an age matched healthy control (F)
SUVR 1.0–1.5. Cerebrospinal ﬂuid examination demonstrated an
elevated t-tau: 1080 pg/mL (NR 146–595); Aβ1–42 360 pg/mL ((NR
627–1322) giving a tau/Aβ1–42 ratio of 3. This case illustrates how
different biomarkers can provide complementary information including
regional neuronal loss, more widespread metabolic dysfunction, as well
as conﬁrming the underlying pathology—in this case, Alzheimer’s
disease. (NB for clinical purposes, 18F-ﬂorbetapir images should be
interpreted on a grey rather than colour scale.)
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activations involving components of this network that may
precede structural brain damage by up to many years.43 44 This
suggests a potential future application in trial settings where
rsfMRI might be used to assess the early impact of candidate
interventions on brain function. Arterial spin labelling MRI has
the potential to demonstrate cerebral blood ﬂow pattern, which
may provide a non-invasive means of obtaining similar informa-
tion to FDG-PET.45
Tau PET imaging
Very recently, a number of tau PET tracers have been developed.
At the time of writing, tau imaging has been performed only in
small number of individuals with AD, and relatively little data is
available.46 Once mature, tau PET imaging may prove valuable
both for differential diagnosis, for prognostication, and as an
outcome measure for clinical trials.
Fluid biomarkers
Biomarkers of amyloid processing
The dominant hypothesis for AD pathogenesis focuses on the
production of toxic, amyloidogenic forms of Aβ.47The APP can
be cleaved either sequentially by β-secretase and γ-secretase
cleavage, producing amyloidogenic forms of Aβ, including
Aβ1-42; or via other pathways to non-amyloidogenic forms.
The β-site APP-cleaving enzyme 1 (BACE1), the major
β-secretase in the brain, can be measured in the CSF. While
some studies have determined higher levels of CSF BACE1 in
patients with AD, results have generally been inconsistent.39
Secreted forms of APP reﬂecting the amyloidogenic and non-
amyloidogenic pathways can also be measured in the CSF, but
again have yet to show consistent results.39 There is also consid-
erable interest in measuring CSF levels of soluble Aβ oligomers,
which may be the most toxic Aβ species.39 Perhaps due to the
fact that these moieties are predicted to have maximum effects
very early in the disease, that they are thought to be present in
very small quantities in CSF, and exist in multiple forms, reliable
assays that show consistent differences between patients and
controls have yet to be validated.
Biomarkers of neuroinﬂammation
A number of pathways related to neuroinﬂammation and more
speciﬁcally microglial activation have been implicated in AD
pathogenesis.48 The astrocytic and oligodendrocytic protein
S100B is elevated in a range of conditions—most notably prion
diseases, but possibly also in mild/moderate AD49 where it may
correlate with rate of brain atrophy.50 The glycoprotein YKL-40
produced by astrocytes or activated microglia, plays a number of
poorly deﬁned roles in CNS inﬂammation, and is increased in
CSF and serum in AD and FTD.51 F2-Isoprostanes, markers of
membrane lipid peroxidation and inﬂammation, have been
shown to predict conversion from MCI to AD.52 Other poten-
tial measures are shown in supplementary table.
Biomarkers for subcortical axonal degeneration and synaptic
dysfunction
Elevated CSF neuroﬁlament light protein (NFL) levels indicate
involvement of predominantly large-calibre myelinated axons,
and are elevated in a range of disorders including stroke, inﬂam-
matory disorders, vascular cognitive impairment and FTD (see
below), but typically not ‘pure’ AD. A range of putative markers
of synaptic function, and notably neurogranin show promise,53
but as yet their use in clinical practice is limited due to the difﬁ-
culties of measuring their low concentration in CSF.
Blood-based and urine-based biomarkers
Despite much research, perhaps for the reasons discussed above,
there are currently no established blood-based biomarkers for
AD. Recent approaches using techniques where several biomar-
kers are analysed simultaneously have identiﬁed promising bio-
markers,54 but the results have unfortunately been hard to
replicate.55 Over 20 such studies, using different clinical cohorts
and different methodology, now exist,55 but the majority of
potential biomarkers, including a set of 10 lipids published in a
recent study56 have only been detected in single studies. A small
number of proteins have been identiﬁed as promising potential
biomarkers across more than one study55; these will however
need to be tested in larger cohorts with prospective follow-up
to determine their clinical utility.
BIOMARKERS OF FTD
The term FTD refers to a group of neurodegenerative disorders
characterised by atrophy of the frontal and temporal lobes.
Prevalence studies suggest that FTD is the second commonest
cause of young onset dementia after AD.57 The two main clin-
ical syndromes of FTD, are behavioural variant FTD (bvFTD),
where there is deterioration in social function and personality;
and primary progressive aphasia (PPA) where there is an insidi-
ous decline in language skills. PPA is further divided into several
subtypes including semantic dementia (SD), progressive non-
ﬂuent aphasia (PNFA), logopenic aphasia (LPA) (typically an AD
variant) and progressive apraxia of speech, based on the pattern
of language breakdown.58 FTD and motor neuron disease show
considerable overlap.59 Approximately a third to a half of
patients with FTD—and particularly those with bvFTD—have a
family history with an autosomal dominant pattern of inherit-
ance. The three most common genes associated with FTD are
hexanucelotide expansions in the C9orf72 gene (also linked to
motor neuron disease phenotypes), mutations in the micro-
tubule associated protein tau (MAPT) gene, and loss of function
mutations in the progranulin (GRN) gene; a number of rarer
genetic causes are also recognised.60
FTD occurring on a sporadic and an autosomal dominant
basis is associated with a range of different underlying patholo-
gies, based on the predominant protein accumulation. These
include tau (4-repeat—progressive supranuclear palsy (PSP) or
corticobasal degeneration (CBD) type, 3-repeat—Pick’s disease
type, and mixed 3-repeat and 4-repeat forms), Tar-DNA binding
protein (TDP)-43 (types A–D) and fused in sarcoma protein
(FUS). In bvFTD any of the pathological variants can be found,
with tau and TDP-43 pathologies representing the majority in
an approximately 50:50 split. SD and the behavioural/prosopag-
nosic presentations of SD (associated with more prominent right
temporal lobe atrophy) are strongly associated with TDP type C
pathology. The pathology of the other language forms is more
complex, and includes AD (particularly in LPA), tauopathy
(with PSP and CBD pathology commonly seen in patients with
apraxia of speech), and TDP-43 proteinopathies. The
co-occurrence of FTD and MND is strongly suggestive of
underlying TDP-43 (typically type B) pathology.60
Currently used biomarkers and their utility
Structural brain imaging
While by no means 100% concordant, pattern of brain atrophy
can provide important clues, not only to clinical phenotype but
also for the underlying pathology and in some cases genetic
basis of disease. Based on clinical phenotype, patients with
bvFTD often show atrophy of mesial frontal, orbitofrontal and
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anterior insula cortices. As the disease progresses there is
involvement of the other frontal neocortical grey matter
regions, the striatum, hippocampi, posterior insulae and parietal
lobes.61 In SD, patients show bilateral but typically highly asym-
metrical (left)-sided atrophy of the anterior temporal lobes
involving the polar and perirhinal cortices and anterior fusiform
gyri. As the disease progresses this degeneration extends caud-
ally into the posterior temporal lobes and rostrally into the pos-
terior, inferior frontal lobes. The structural imaging ﬁndings in
PNFA are very heterogeneous and scans are often remarkably
normal in the earliest stages. Typically, however, there may be
volume loss involving the anterior perisylvian, and inferior oper-
cular and insular portions of the dominant hemisphere.62 As the
disease progresses there is involvement of the dorsolateral pre-
frontal cortex, temporal cortex, orbital and anterior cingulate
regions and parietal lobe.63 MRI-based quantiﬁcation of
atrophy rates of whole brain or lobar volumes are potentially
useful objective biomarkers of progression in FTD64 .
When classiﬁed on the basis of pathology, 3-repeat tau Pick’s
disease is often associated with atrophy involving the prefrontal
cortex with severe dorsolateral frontal atrophy, which can be
markedly asymmetric.65 Patients with PSP and CBD can often
present with an FTD-like syndrome, in which case certain fea-
tures on structural imaging may be particularly helpful: patients
with PSP classically have atrophy of the rostral midbrain,
leading to the so-called Hummingbird sign on imaging66 this is
however not always present in dementia dominant cases. In PSP
and CBD atrophy may affect the posterior frontal lobes, while
in CBD the atrophy will often involve the parietal lobes and can
be very asymmetric. However, in pathologically ascertained
series, the atrophy in ‘cognitive’ CBD is often surprisingly non-
speciﬁc and symmetrical.65 67
Certain patterns of atrophy have been associated, although by
no means invariably, with the different TDP-43 subtypes. Thus
TDP-A is often associated with asymmetric atrophy involving
the frontal, temporal and parietal lobes; TDP-B is associated
with frontal atrophy, in keeping with the association of this
pathology with the clinical syndrome of FTD/MND; and
TDP-C with asymmetric anterior temporal lobe atrophy, consist-
ent with the close clinicopathological correlation with SD.65
FUS pathology is associated with frontal atrophy often with
striking atrophy of the caudate nuclei.65
From a genetic perspective, individuals with tau (MAPT)
mutations, often have very symmetrical anterior and inferior
medial temporal lobe atrophy, with involvement of the orbito-
frontal cortices.68 In GRN mutations atrophy is typically highly
asymmetric involving the temporal, inferior frontal and parietal
lobes.68 No clear and consistent pattern of atrophy has yet
emerged in C9orf72 mutation cases: atrophy is often symmet-
rical, but not always; and while often relatively mild, can on
occasions be very widespread. It can involve the frontal and
temporal lobes, and thalami, but may extend to the occipital
lobe and cerebellum,69 where TDP-43 or p62-positive inclusions
are frequently found at histology.
Functional imaging
FDG-PET typically shows frontal and temporal lobe hypometa-
bolism in FTD. Demonstrating hypometabolism may be particu-
larly valuable in cases with behavioural change with normal
structural imaging, where a non-degenerative FTD-mimic is
considered.4 Where the differential diagnosis is between AD
and FTD, amyloid PET imaging may be very useful in ruling in/
out the presence of amyloid pathology; this may prove particu-
larly valuable in the progressive aphasias given their
considerable clinical and pathological heterogeneity and also in
corticobasal syndrome where it is difﬁcult to distinguish CBD
from AD as the underling cause.70
Cerebrospinal ﬂuid
In the absence of speciﬁc CSF biomarkers for TDP-43, or to dis-
tinguish the different tauopathies, currently the most important
clinical utility of CSF biomarkers in FTD is to distinguish under-
lying AD from other FTD pathologies. In particular, if CSF is
appropriately handled and measured, reduction of Aβ1-42 level
would not be expected in cases with tau or TDP-43 proteinopa-
thies. Several studies71 have shown that CSF t-tau levels are
lower in FTD than those seen in AD, but higher than that seen
in controls,71 with t-tau levels correlating with neuropsycho-
logical, neuroimaging and prognosis in patients with FTD72;
however in many cases with FTD, CSF t-tau levels can be
normal. As discussed above, p-tau elevation is typically seen in
AD rather than other neurodegenerative diseases, with one
study of FTD ﬁnding that a reduced p-tau to t-tau ratio predicts
TDP-43 pathology in FTD.73
Emerging and future biomarkers
Imaging
As with AD, DTI and rsfMRI have considerable potential to
detect presymptomatic and disease-speciﬁc network breakdown
in the various forms of FTD. Speciﬁc patterns of DTI break-
down have been associated with the clinical presentations in
FTD74 and on a group level DTI may be helpful in discriminat-
ing between tau and TDP-43 proteinopathies, the latter showing
greater white matter damage.75 There is considerable evidence
again at least on a group level that breakdown in both func-
tional connectivity in FTD involves different functional net-
works compared with AD, for example, targeting the so-called
salience (environmentally directed) as opposed to default mode
(internalised thought) network.76 Within the FTD spectrum,
different diseases may have characteristic, molecularly deter-
mined network signatures or ‘nexopathies’77 It is however not
clear if and how these techniques can be applied on an individ-
ual basis.
As with AD, ASL may provide a non-invasive alternative to
FDG-PET, providing an MRI-based measure of cerebral perfu-
sion. It is not yet clear to what extent available tau PET ligands
bind different subtypes of tau pathology or how reliably they
can distinguish tau, AD and TDP-43 pathologies, or whether
this technique will prove a useful means of reliably distinguish-
ing the various FTD pathologies in vivo. To date, no speciﬁc
TDP-43-based ligands are available.
Fluid biomarkers
Tar-DNA binding protein-43
Increased TDP-43 levels have been found in CSF in FTD and
MND cases.78 Kasai et al79 found increased levels in MND par-
ticularly early in disease progression, suggesting that CSF
TDP-43 may be an early marker of TDP-43 proteinopathies.
Patients with C9orf72 expanded repeats or GRN mutations,
where TDP-43 pathology can reliably be predicted in vivo, have
been shown to have increased plasma and CSF levels of phos-
phorylated TDP-43 compared with other patients with FTD
and normal controls; this same study found plasma levels of
total TDP-43 to be decreased in mutation carriers, possibly due
to alterations in the ratio of phosphorylated to total TDP-43 in
favour of the former.80
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Progranulin
Serum progranulin levels show considerable promise as a bio-
marker of underlying progranulin mutations.81 Null mutations
have been associated with a fourfold reduction in plasma pro-
granulin levels compared to controls,82 with missense mutations
resulting in a smaller reduction.83 Studies of large, mixed, FTD
populations are required to determine the sensitivity and speciﬁ-
city of serum progranulin as a predictor of mutations and of the
underlying pathology.
Neuroﬁlament
Two recent studies84 85 have found that elevated CSF NFL
levels correlate with FTD disease severity.84 The highest levels
were in tau negative cases and SD,85 where TDP-43 is the pre-
dominant pathology. Different levels, and perhaps forms of neu-
roﬁlament may therefore ﬁnd utility in differentiating the
underlying pathology in cases of FTD, in distinguishing AD
from non-AD pathology, and for tracking disease in patients
with conﬁrmed disease; however, as NFL is elevated in several
other conditions—and notably vascular disease—its utility in
isolated unselected cases is less clear.
Biomarkers of neuroinﬂammation
As with AD, there is considerable interest in inﬂammation in
FTD. A recent study86 showed increased serum TNF-α in two
different conditions strongly associated with TDP-43 pathology,
that is, SD and GRN mutation carriers. A number of inﬂamma-
tory biomarkers have been reported to be elevated in FTD. One
study has suggested that IL-23 may be speciﬁc for FTD asso-
ciated with tau, while IL-17 may be speciﬁc for FTD associated
with TDP-43 pathology; this however requires further
conﬁrmation.87
BIOMARKERS OF DLB
DLB, the second most common cause of neurodegenerative
dementia after AD, is characterised by a progressive deterioration
in cognition, with core features including ﬂuctuating cognition
and variations in alertness; recurrent visual hallucinations; and fea-
tures of motor parkinsonism.88 Neuropsychological testing typic-
ally reveals deﬁcits in attention, executive function and
visuospatial ability.88 The core pathology of DLB is the presence of
Lewy bodies in brainstem, limbic regions or cortex comprising
α-synuclein. DLB is widely thought to be on a continuum with
Parkinson’s disease dementia, and at autopsy is commonly asso-
ciated with other pathologies including AD and vascular disease.89
Currently used biomarkers and their utility
Structural brain imaging
Typically, DLB is associated with preserved volume of the
medial temporal lobes relative to that seen in AD.90 The extent
to which hippocampal sparing as a marker of DLB as opposed
to AD can be applied in individual cases is limited, with some
studies ﬁnding that MRI is not useful in differentiating DLB
from AD.91
Functional imaging
Current clinical diagnostic criteria include PET/SPECT (eg, 123
I-FP CIT—DaTSCAN) measures of dopaminergic loss in the
basal ganglia as a suggestive feature of DLB.88 123 I-FP CIT
SPECT imaging can be used to differentiate DLB from AD and
some forms of FTD92 with reasonable diagnostic accuracy (sen-
sitivity around 80% with 90% speciﬁcity), but is less useful in
differentiating DLB from atypical parkinsonian conditions
which can also show nigrostriatal abnormalities.93 FDG-PET
occipital hypoperfusion may have utility in distinguishing DLB
from AD,94 although changes can be seen in patients with pos-
terior variants of AD, and in CBD. Several studies have found
decreased metaiodobenzylguanidine myocardial scintigraphy
reﬂecting impaired sympathetic nervous system function in DLB
compared with AD.93
Emerging and future biomarkers
Imaging
Amyloid PET imaging is likely to have limited utility in distin-
guishing AD from DLB as both may have similar cortical
amyloid load,95 with a recent review of 12 studies ﬁnding
amyloid PET positivity in 57% of clinically diagnosed DLB
cases.28 However, it may have a role in differentiating DLB
from other parkinsonian conditions. There are as yet no
α-synuclein PET ligands available.
CSF
Levels of CSF tau are very variable in DLB, typically being
lower than in AD95 although in rapidly progressive cases they
can be very elevated. Studies examining Aβ1-42 levels have
found similar levels between DLB and AD.96 Some studies have
reported reduced levels of CSF α-synuclein in DLB,97 while
others have not.98 An oxidised form of Aβ1-40 has been pro-
posed as a potential DLB marker.99 However, this oxidation
may appear in CSF postsampling and the results need replica-
tion before any conclusions can be drawn on the diagnostic use-
fulness of this Aβ isoform.
CONCLUSION
In the correct clinical context, imaging and CSF biomarkers can
provide in vivo evidence for the various pathological processes
underpinning the different causes of dementia, which can in
turn be used to improve diagnostic sensitivity and speciﬁcity, as
inclusion and exclusion criteria and outcome measures in clin-
ical trials, and to provide insights into pathogenesis. Biomarkers
are now being incorporated into new diagnostic criteria (see
table 2), and are being used—at least on a research basis—to
allow for presymptomatic or paucity-symptomatic diagnosis.
While the speciﬁc biomarkers vary across different dementias,
there are common themes including their potential ability to
allow presymptomatic diagnosis, track disease progression by
the sequence of changes in biomarkers, and reﬂect underlying
pathology. Many of the biomarkers have shown utility on a
group level, but how they can be applied on an individual level
and in clinical practice requires further investigation. This
should not however diminish their importance especially in the
setting of clinical trials, for patient stratiﬁcation for entry and as
outcome measures. No one biomarker is diagnostic of any one
condition in its own right, each has limitations, and interpret-
ation should always be done in the appropriate clinical context.
Future studies will beneﬁt from ever more sensitive and auto-
mated techniques, which will hopefully make blood-based and/
or urine-based biomarkers a reality. Critical to the development
and validation of any biomarker is standardisation of sample/
scan collection, analysis and interpretation; and ultimately post-
mortem conﬁrmation of diagnosis.
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